Nat Med

Ubrogepant may prevent migraine onset when taken early

May 26, 2025

Ubrogepant, when administered during the prodromal phase, may not only alleviate early symptoms but also potentially prevent full migraine attacks, supporting a proactive treatment approach for patients with predictable prodrome patterns.

Study details: The phase 3, double-blind, placebo-controlled, crossover PRODROME trial evaluated ubrogepant 100 mg for its ability to prevent headache and resolve prodromal symptoms when taken during the premonitory phase of migraine. Participants (n = 477) were selected based on their ability to reliably identify prodromal symptoms predicting headache onset within 1 to 6 hours.

Results: Ubrogepant significantly improved multiple prodromal symptoms compared with placebo. At 2 to 4 hours post-dose, symptom resolution rates were higher for photophobia (19.5% vs. 12.5%), fatigue (27.3% vs. 16.8%), neck pain (28.9% vs. 15.9%), and phonophobia (50.7% vs. 35.8%), with odds ratios ranging from 1.72 to 2.04. Improvements in cognitive symptoms were also observed, including difficulty concentrating (odds ratio [OR], 4.26 at 1 hour) and difficulty thinking (OR, 2.05 at 6 hours). Dizziness resolution at 24 hours was also greater with ubrogepant (88.5% vs. 82.3%).

Source:

Goadsby PJ, et al. (2025, May 12). Nat Med. Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. https://pubmed.ncbi.nlm.nih.gov/40355614/